Protara Therapeutics, Inc.
TARA
$3.40
-$0.12-3.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -24.93% | -13.78% | 15.77% | -22.66% | 73.77% |
| Total Depreciation and Amortization | -23.36% | 6.33% | 6.41% | 7.79% | 42.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -46.13% | -36.65% | -28.46% | -23.90% | -94.77% |
| Change in Net Operating Assets | 1,199.12% | -1.34% | 2,394.74% | 86.63% | -109.19% |
| Cash from Operations | -6.99% | -28.55% | 18.29% | 19.47% | -73.10% |
| Capital Expenditure | -- | 78.38% | -2,650.00% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 54.98% | -558.02% | -86.58% | 134.14% | 179.16% |
| Cash from Investing | 54.98% | -560.80% | -86.82% | 134.28% | 179.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -18.75% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 100.00% | -- | -18.75% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,808.58% | -17,911.43% | 188.57% | 508.96% | 124.89% |